Big news for dealing with coronavirus and for the healthcare and life sciences sector in Catalonia: pharmaceutical company Reig Jofre, a member of CataloniaBio & HealthTech, has reached a deal with Janssen of Johnson & Johnson to manufacture its Covid-19 vaccine in Phase III clinical trials.

Reig Jofre has extensive experience in manufacturing injectable and freeze-dried products, both its own and for third parties. In the first quarter of 2021, the company will launch a new state-of-the-art plant in Sant Joan Despí (Barcelona) that will help meet the need for fast, secure deployment of the Covid-19 vaccine. The pharmaceutical company will be able to manufacture 250 million dosages a year. The vaccine will be distributed by Janssen.

Ignasi Biosca, CEO of Reig Jofre and former president of CataloniaBio & HealthTech (2014-2018), explains, “We are proud to see that Reig Jofre’s sustained effort investing in technology and industrial capabilities will now be decisive in deploying the Covid-19 vaccine in many countries.”

Biosca also highlights the importance of having been chosen by Janssen as one of its partners: “It will give us the opportunity to demonstrate the strategic value of having a strong, competitive, technologically advanced industry to overcome a critical situation like this one.”

More information

Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Destacadas

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

En nuestro post hablamos sobre este interesante tipo de célula del si...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Diapositiva de Fotos